Denali Therapeutics (DNLI) Stock Forecast, Price Target & Predictions
DNLI Stock Forecast
Denali Therapeutics stock forecast is as follows: an average price target of $40.00 (represents a 58.42% upside from DNLI’s last price of $25.25) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
DNLI Price Target
The average price target for Denali Therapeutics (DNLI) is $40.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $22.00. This represents a potential 58.42% upside from DNLI's last price of $25.25.
DNLI Analyst Ratings
According to 4 Wall Street analysts, Denali Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for DNLI stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Denali Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Tazeen Ahmad | Bank of America Securities | $29.00 | $25.12 | 15.45% | 14.85% |
| Sep 03, 2024 | Marank Mamtani | B.Riley Financial | $33.00 | $25.12 | 31.37% | 30.69% |
| Sep 03, 2024 | Salveen Richter | Goldman Sachs | $46.00 | $25.12 | 83.12% | 82.18% |
| Sep 03, 2024 | Paul Mattels | Stifel Nicolaus | $22.00 | $25.12 | -12.42% | -12.87% |
| Aug 05, 2021 | Salveen Richter | Goldman Sachs | $112.00 | $52.93 | 111.60% | 343.56% |
| May 18, 2021 | Esther Rajavelu | UBS | $70.00 | $55.51 | 26.10% | 177.23% |
The latest Denali Therapeutics stock forecast, released on Sep 04, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $29.00, which represents a 15.45% increase from the stock price at the time of the forecast ($25.12), and a 14.85% increase from DNLI last price ($25.25).
Denali Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 4 | 4 |
| Avg Price Target | $32.50 | $32.50 | $32.50 |
| Last Closing Price | $25.25 | $25.25 | $25.25 |
| Upside/Downside | 28.71% | 28.71% | 28.71% |
In the current month, the average price target of Denali Therapeutics stock is $32.50, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 28.71% increase as opposed to Denali Therapeutics's last price of $25.25. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Feb 29, 2024 | Goldman Sachs | Buy | Buy | Hold |
| Feb 28, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Feb 28, 2024 | Wedbush | Buy | Buy | Hold |
| Sep 06, 2023 | B. Riley Securities | - | Buy | Initialise |
| Dec 05, 2022 | Cowen & Co. | - | Outperform | Initialise |
Denali Therapeutics's last stock rating was published by Goldman Sachs on Sep 03, 2024. The company gave DNLI a "Buy" rating, the same as its previous rate.
Denali Therapeutics Financial Forecast
Denali Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $1.27M | - | $35.14M | $10.28M | $3.56M | - | $42.14M | $12.51M | $5.29M | $22.94M | $7.92M | $316.81M | $9.39M | $5.85M | $3.60M | $4.67M | $13.60M | $4.20M | $4.21M | $1.20M | $1.65M |
| Avg Forecast | $25.00M | $25.00M | $25.00M | $25.00M | $7.21M | $6.00M | $10.00M | $14.02M | $7.98M | $11.16M | $39.51M | $28.72M | $13.12M | $17.02M | $44.66M | $33.36M | $44.82M | $30.28M | $27.92M | $31.62M | $78.21M | $494.27M | $3.67M | $5.01M | $8.62M | $9.33M | $3.35M | $9.12M | $786.18K | $558.64K |
| High Forecast | $25.00M | $25.00M | $25.00M | $25.00M | $7.21M | $9.34M | $10.00M | $14.02M | $20.81M | $11.16M | $39.51M | $28.72M | $13.12M | $17.02M | $44.66M | $55.60M | $74.70M | $50.46M | $46.53M | $52.71M | $130.35M | $823.78M | $6.12M | $8.34M | $14.36M | $15.55M | $5.58M | $15.20M | $943.42K | $670.37K |
| Low Forecast | $25.00M | $25.00M | $25.00M | $25.00M | $7.21M | $2.55M | $10.00M | $14.02M | $901.86K | $11.16M | $39.51M | $28.72M | $13.12M | $17.02M | $44.66M | $4.28M | $5.75M | $3.88M | $3.58M | $4.05M | $10.03M | $63.37M | $470.50K | $641.90K | $1.10M | $1.20M | $429.59K | $1.17M | $628.95K | $446.91K |
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 11 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.11% | - | 1.22% | 0.78% | 0.21% | - | 1.26% | 0.28% | 0.17% | 0.82% | 0.25% | 4.05% | 0.02% | 1.59% | 0.72% | 0.54% | 1.46% | 1.25% | 0.46% | 1.52% | 2.95% |
Denali Therapeutics's average Quarter revenue forecast for Dec 23 based on 11 analysts is $7.98M, with a low forecast of $901.86K, and a high forecast of $20.81M. DNLI's average Quarter revenue forecast represents a 530.22% increase compared to the company's last Quarter revenue of $1.27M (Sep 23).
Denali Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 11 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-113.80M | - | $-120.81M | $-101.25M | $-105.34M | - | $-64.42M | $-73.74M | $-82.40M | $-58.49M | $-67.93M | $247.83M | $-56.02M | $-56.53M | $-54.79M | $-51.90M | $-44.48M | $-57.01M | $-36.59M | $-33.04M | $-52.87M |
| Avg Forecast | $-16.79M | $-16.79M | $-16.79M | $-16.79M | $-4.84M | $-4.03M | $-6.72M | $-73.40M | $-5.36M | $-7.49M | $-26.53M | $-66.73M | $-8.81M | $-67.45M | $-29.99M | $-60.66M | $-39.57M | $-53.32M | $-37.94M | $-42.54M | $-52.52M | $-109.96M | $-60.30M | $-56.71M | $-53.68M | $-50.84M | $-38.42M | $-35.67M | $-17.45M | $-50.23M |
| High Forecast | $-16.79M | $-16.79M | $-16.79M | $-16.79M | $-4.84M | $-1.71M | $-6.72M | $-58.72M | $-605.62K | $-7.49M | $-26.53M | $-53.39M | $-8.81M | $-53.96M | $-29.99M | $-48.53M | $-31.66M | $-42.65M | $-30.35M | $-34.04M | $-6.73M | $-87.97M | $-48.24M | $-45.37M | $-42.95M | $-40.67M | $-30.73M | $-28.54M | $-13.96M | $-40.18M |
| Low Forecast | $-16.79M | $-16.79M | $-16.79M | $-16.79M | $-4.84M | $-6.27M | $-6.72M | $-88.09M | $-13.98M | $-7.49M | $-26.53M | $-80.08M | $-8.81M | $-80.94M | $-29.99M | $-72.80M | $-47.48M | $-63.98M | $-45.53M | $-51.05M | $-87.53M | $-131.96M | $-72.36M | $-68.05M | $-64.42M | $-61.01M | $-46.10M | $-42.81M | $-20.94M | $-60.27M |
| Surprise % | - | - | - | - | - | - | - | - | - | 15.19% | - | 1.81% | 11.50% | 1.56% | - | 1.06% | 1.86% | 1.55% | 1.54% | 1.60% | -4.72% | 0.51% | 0.94% | 0.97% | 0.97% | 0.88% | 1.48% | 1.03% | 1.89% | 1.05% |
4 analysts predict DNLI's average Quarter EBITDA for Mar 21 to be $-42.54M, with a high of $-34.04M and a low of $-51.05M. This is -117.17% lower than Denali Therapeutics's previous annual EBITDA (Dec 20) of $247.83M.
Denali Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 11 |
| Net Income | - | - | - | - | - | - | - | - | - | $-99.35M | - | $-88.70M | $-98.68M | $-99.11M | - | $-63.94M | $-75.26M | $-84.59M | $-60.69M | $-70.04M | $244.88M | $-58.23M | $-58.76M | $-56.76M | $-54.02M | $-46.26M | $-58.34M | $-38.99M | $-35.37M | $-54.72M |
| Avg Forecast | $-114.18M | $-114.82M | $-114.97M | $-115.61M | $-108.31M | $-104.67M | $-115.76M | $-75.82M | $-135.74M | $-136.72M | $-117.22M | $-68.93M | $-133.01M | $-69.24M | $-77.90M | $-62.66M | $-40.38M | $-54.73M | $-39.37M | $-43.86M | $41.65B | $-114.31M | $-62.68M | $-58.75M | $-55.89M | $-52.87M | $-39.31M | $-38.02M | $-18.68M | $-51.99M |
| High Forecast | $-114.18M | $-114.82M | $-114.97M | $-115.61M | $-108.31M | $-77.22M | $-115.76M | $-60.66M | $-117.53M | $-136.72M | $-117.22M | $-55.14M | $-133.01M | $-55.39M | $-77.90M | $-50.13M | $-32.31M | $-43.79M | $-31.49M | $-35.09M | $49.99B | $-91.45M | $-50.14M | $-47.00M | $-44.71M | $-42.29M | $-31.45M | $-30.41M | $-14.94M | $-41.59M |
| Low Forecast | $-114.18M | $-114.82M | $-114.97M | $-115.61M | $-108.31M | $-126.98M | $-115.76M | $-90.99M | $-158.92M | $-136.72M | $-117.22M | $-82.71M | $-133.01M | $-83.09M | $-77.90M | $-75.19M | $-48.46M | $-65.68M | $-47.24M | $-52.64M | $33.32B | $-137.17M | $-75.21M | $-70.51M | $-67.07M | $-63.44M | $-47.18M | $-45.62M | $-22.41M | $-62.39M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.73% | - | 1.29% | 0.74% | 1.43% | - | 1.02% | 1.86% | 1.55% | 1.54% | 1.60% | 0.01% | 0.51% | 0.94% | 0.97% | 0.97% | 0.88% | 1.48% | 1.03% | 1.89% | 1.05% |
Denali Therapeutics's average Quarter net income forecast for Mar 21 is $-43.86M, with a range of $-52.64M to $-35.09M. DNLI's average Quarter net income forecast represents a -117.91% decrease compared to the company's last Quarter net income of $244.88M (Dec 20).
Denali Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 11 |
| SG&A | - | - | - | - | - | - | - | - | - | $25.32M | - | $27.14M | $23.52M | $23.26M | - | $22.54M | $21.76M | $19.32M | $19.05M | $18.94M | $17.99M | $15.80M | $13.97M | $12.55M | $10.88M | $11.21M | $15.08M | $9.31M | $8.84M | $6.90M |
| Avg Forecast | $23.21M | $23.21M | $23.21M | $23.21M | $6.69M | $5.57M | $9.29M | $13.02M | $7.41M | $10.36M | $36.69M | $23.82M | $12.18M | $15.81M | $41.47M | $21.66M | $11.68M | $12.50M | $12.35M | $11.86M | $72.62M | $31.03M | $3.41M | $4.65M | $8.00M | $8.66M | $3.11M | $9.08M | $730.04K | $518.75K |
| High Forecast | $23.21M | $23.21M | $23.21M | $23.21M | $6.69M | $8.67M | $9.29M | $13.02M | $19.33M | $10.36M | $36.69M | $28.59M | $12.18M | $18.98M | $41.47M | $25.99M | $14.01M | $15.00M | $14.82M | $14.23M | $121.04M | $37.23M | $5.68M | $7.75M | $13.34M | $14.44M | $5.19M | $10.89M | $876.04K | $622.50K |
| Low Forecast | $23.21M | $23.21M | $23.21M | $23.21M | $6.69M | $2.37M | $9.29M | $13.02M | $837.45K | $10.36M | $36.69M | $19.06M | $12.18M | $12.65M | $41.47M | $17.33M | $9.34M | $10.00M | $9.88M | $9.49M | $9.31M | $24.82M | $436.89K | $596.06K | $1.03M | $1.11M | $398.91K | $7.26M | $584.03K | $415.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | 2.44% | - | 1.14% | 1.93% | 1.47% | - | 1.04% | 1.86% | 1.55% | 1.54% | 1.60% | 0.25% | 0.51% | 4.10% | 2.70% | 1.36% | 1.29% | 4.85% | 1.03% | 12.11% | 13.29% |
Denali Therapeutics's average Quarter SG&A projection for Dec 23 is $7.41M, based on 11 Wall Street analysts, with a range of $837.45K to $19.33M. The forecast indicates a -70.72% fall compared to DNLI last annual SG&A of $25.32M (Sep 23).
Denali Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 10 | 11 | 5 | 5 | 9 | 5 | 4 | 4 | 8 | 6 | 5 | 5 | 4 | 6 | 4 | 6 | 4 | 5 | 3 | 5 | 3 | 8 | 11 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.72 | - | $-0.65 | $-0.74 | $-0.80 | - | $-0.52 | $-0.62 | $-0.69 | $-0.50 | $-0.58 | $2.04 | $-0.54 | $-0.56 | $-0.55 | $-0.56 | $-0.48 | $-0.61 | $-0.41 | $-0.38 | $-0.59 |
| Avg Forecast | $-0.68 | $-0.68 | $-0.68 | $-0.68 | $-0.64 | $-0.62 | $-0.69 | $-0.69 | $-0.80 | $-0.81 | $-0.69 | $-0.70 | $-0.79 | $-0.80 | $-0.52 | $-0.51 | $-0.50 | $-0.46 | $-0.41 | $-0.34 | $-0.09 | $3.15 | $-0.61 | $-0.57 | $-0.58 | $-0.56 | $-0.46 | $-0.40 | $-0.13 | $-0.19 |
| High Forecast | $-0.68 | $-0.68 | $-0.68 | $-0.68 | $-0.64 | $-0.46 | $-0.69 | $-0.69 | $-0.70 | $-0.81 | $-0.69 | $-0.70 | $-0.79 | $-0.80 | $-0.52 | $0.07 | $0.07 | $0.06 | $0.05 | $0.05 | $0.01 | $5.87 | $0.08 | $0.08 | $0.08 | $0.07 | $0.06 | $0.05 | $-0.11 | $-0.15 |
| Low Forecast | $-0.68 | $-0.68 | $-0.68 | $-0.68 | $-0.64 | $-0.75 | $-0.69 | $-0.69 | $-0.94 | $-0.81 | $-0.69 | $-0.70 | $-0.79 | $-0.80 | $-0.52 | $-0.95 | $-0.93 | $-0.87 | $-0.76 | $-0.63 | $-0.17 | $-0.42 | $-1.13 | $-1.06 | $-1.08 | $-1.05 | $-0.86 | $-0.75 | $-0.16 | $-0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.89% | - | 0.93% | 0.94% | 1.00% | - | 1.02% | 1.25% | 1.49% | 1.22% | 1.71% | -21.83% | -0.17% | 0.92% | 0.96% | 0.97% | 0.85% | 1.33% | 1.02% | 2.92% | 3.11% |
According to 4 Wall Street analysts, Denali Therapeutics's projected average Quarter EPS for Mar 21 is $-0.34, with a low estimate of $-0.63 and a high estimate of $0.05. This represents a -116.65% decrease compared to DNLI previous annual EPS of $2.04 (Dec 20).
Denali Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| BCEL | Atreca | $0.09 | $4.00 | 4344.44% | Buy |
| HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
| FDMT | 4D Molecular Therapeutics | $15.07 | $44.57 | 195.75% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| DAWN | Day One Biopharmaceuticals | $14.20 | $38.80 | 173.24% | Buy |
| BDTX | Black Diamond Therapeutics | $5.40 | $14.75 | 173.15% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| APLS | Apellis Pharmaceuticals | $41.05 | $75.81 | 84.68% | Buy |
| TVTX | Travere Therapeutics | $10.98 | $19.50 | 77.60% | Buy |
| SWTX | SpringWorks Therapeutics | $38.75 | $67.33 | 73.75% | Buy |
| AKRO | Akero Therapeutics | $26.41 | $43.50 | 64.71% | Buy |
| LEGN | Legend Biotech | $48.29 | $78.78 | 63.14% | Buy |
| DNLI | Denali Therapeutics | $25.25 | $40.00 | 58.42% | Buy |
| ASND | Ascendis Pharma | $119.15 | $175.15 | 47.00% | Buy |
| BGNE | BeiGene | $191.32 | $247.75 | 29.50% | Buy |
| RNA | Avidity Biosciences | $40.46 | $50.00 | 23.58% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $41.84 | $51.20 | 22.37% | Buy |
| BPMC | Blueprint Medicines | $86.43 | $101.50 | 17.44% | Buy |
| PCVX | Vaxcyte | $111.58 | $117.00 | 4.86% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
DNLI Forecast FAQ
Is Denali Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Denali Therapeutics (DNLI) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of DNLI's total ratings.
What is DNLI's price target?
Denali Therapeutics (DNLI) average price target is $40 with a range of $22 to $70, implying a 58.42% from its last price of $25.25. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Denali Therapeutics stock go up soon?
According to Wall Street analysts' prediction for DNLI stock, the company can go up by 58.42% (from the last price of $25.25 to the average price target of $40), up by 177.23% based on the highest stock price target, and down by -12.87% based on the lowest stock price target.
Can Denali Therapeutics stock reach $40?
DNLI's highest twelve months analyst stock price target of $70 supports the claim that Denali Therapeutics can reach $40 in the near future.
What is Denali Therapeutics's current price target trend?
4 Wall Street analysts forecast a $32.5 price target for Denali Therapeutics (DNLI) this month, up 28.71% from its last price of $25.25. Compared to the last 3 and 12 months, the average price target increased by 28.71% and increased by 28.71%, respectively.
What are Denali Therapeutics's analysts' financial forecasts?
Denali Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $37.23M (high $40.57M, low $33.78M), average EBITDA is $-88.992M (high $-71.992M, low $-106M), average net income is $-405M (high $-362M, low $-442M), average SG&A $34.58M (high $37.68M, low $31.37M), and average EPS is $-2.642 (high $-2.479, low $-2.774). DNLI's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $100M (high $100M, low $100M), average EBITDA is $-67.153M (high $-67.153M, low $-67.153M), average net income is $-460M (high $-460M, low $-460M), average SG&A $92.86M (high $92.86M, low $92.86M), and average EPS is $-2.722 (high $-2.722, low $-2.722).
Did the DNLI's actual financial results beat the analysts' financial forecasts?
Based on Denali Therapeutics's last annual report (Dec 2023), the company's revenue was $330.53M, beating the average analysts forecast of $87.37M by 278.30%. Apple's EBITDA was $-197M, beating the average prediction of $-106M by 85.36%. The company's net income was $-145M, missing the average estimation of $-459M by -68.33%. Apple's SG&A was $103.35M, beating the average forecast of $78.28M by 32.03%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-3.009 by -99.96%. In terms of the last quarterly report (Sep 2023), Denali Therapeutics's revenue was $1.27M, missing the average analysts' forecast of $11.16M by -88.64%. The company's EBITDA was $-114M, beating the average prediction of $-7.493M by 1418.76%. Denali Therapeutics's net income was $-99.353M, missing the average estimation of $-137M by -27.33%. The company's SG&A was $25.32M, beating the average forecast of $10.36M by 144.43%. Lastly, the company's EPS was $-0.72, missing the average prediction of $-0.81 by -11.09%